PRESS ROOM

PSYCHECEUTICAL IN THE NEWS

Psycheceutical’s Topical PTSD Drug Poised for Human Trials

Read Feature

Psycheceutical Developing The First Ever Topical Psychedelic Cream To Treat PTSD

Read Feature

Psycheceutical Listed as 1 of 7 Psychedelic Stocks to Watch

Read Feature

Shark Tank’s Kevin Harrington Invests In Psychedelics Company Psycheceutical

Read Feature

Kevin Harrington Becomes The Latest ‘Shark Tank’ Judge To Enter The Psychedelics Space

Read Feature

Psycheceutical Announces Julian Bailes, M.D. as Principal Medical Advisor

Read Feature

Psycheceutical Bioscience, Inc. Announces Medical Advisory Board

Read Feature

Armed With Two Patents, Psycheceutical Plans To Transform Psychedelic Drug Delivery

Read Feature

Psycheceutical Licenses New Delivery Technologies For Psychedelic Medicines

Read Feature

Biotech Company Earns Two Patents for Targeted Delivery of Psychedelic Medicines

Read Story

Novel Psychedelic Treatment Approach Bypasses Hallucinogenic Effects to Allow Widespread Adoption

Read Story

Psychedelic Business Spotlight: Psycheceutical, Inc., Announces Exclusive License of Two Major Patents

Read Story

PODCASTS

Play Video

Chad Harman, CEO of Psycheceutical, Sits in the Psychedelic Invest Investor Hotseat

Psycheceutical: Frontiers of Treatment with Dr. Thomas Cabell and Chad Harman

Psycheceutical’s Kaia Roman on the NuroFlex Podcast

Psycheceutical’s Zappy Zapolin On The Psychedelic Invest Podcast

Psycheceutical CEO, Chad Harman, On The Street Smart Podcast

PRESS RELEASES

02/15/2023 in Press Releases

Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSD

Psycheceutical ​​enters into agreement with iNGENū to conduct ​human ​clinical trials of NeuroDirect™ ketamine topical ​in Australia
Read More
02/02/2023 in Press Releases

Psycheceutical Announces Completion of Pre-IND Meeting with FDA for Topical Ketamine Drug to Treat PTSD

Company intends to pursue 505(b)(2) regulatory pathway for novel topical formulation of ketamine for the treatment of PTSD
Read More
01/26/2023 in Press Releases

Psycheceutical Bioscience Files Provisional Patent Application for Novel Ketamine Topical for the Treatment of PTSD

Topical ketamine formulations could improve the methods of treating post-traumatic stress disorder (PTSD)
Read More
01/10/2023 in Press Releases

Psycheceutical Announces Julian Bailes, M.D. as Board Member and Chief Medical Officer

Renowned neurosurgeon to oversee the development of breakthrough psychedelic therapeutics
Read More
11/29/2022 in Press Releases

Dr. Aric Logsdon Joins Psycheceutical Bioscience, Inc. as Company’s Scientific Director

Dr. Logsdon’s expertise to help guide the company’s further research and development for its patented drug-delivery technology.
Read More
10/18/2022 in Press Releases

Psycheceutical Bioscience, Inc. Announces Medical Advisory Board

To be led by accomplished Neurosurgeon Dr. Julian Bailes, the Medical Advisory Board will support the Company in developing breakthrough psychedelic medicine technologies for mental health treatments...
Read More
10/04/2022 in Press Releases

Psycheceutical Bioscience, Inc.’s Zappy Zapolin Added to The Benzinga Psychedelics Advisory Council

Chief Visionary Officer of Psycheceutical, Zappy Zapolin, will join other prominent leaders in Psychedelics on Benzinga’s Council Board.
Read More
08/16/2022 in Press Releases

Psycheceutical Bioscience, Inc. Enters into Exclusive Option to Acquire Vici Health Sciences

Vici Health Sciences CEO Anish Dhanarajan to join Psycheceutical as Research and Development Advisor.
Read More
05/10/2022 in Press Releases

Psycheceutical Brings on Original Shark from ‘Shark Tank,’ Kevin Harrington, as Investor and Strategic Advisor

Famed entrepreneur excited about the company’s development of psychedelic pharmaceutical medicines to treat the widespread mental health crisis.
Read More
03/29/2022 in Press Releases

Psycheceutical’s Chief Visionary Officer Zappy Zapolin Speaking at Legacy Investment Summit Alongside Entrepreneur Peter Diamandis

Psycheceutical Chief Visionary Officer, Zappy Zapolin, will be a featured presenter at the esteemed Legacy Investment Summit 2022, to be held at the Mandarin Oriental Hotel in Washington, D.C. on March 31…
Read More
03/15/2022 in Press Releases

Psycheceutical Announces Agreement with Vici Health Sciences

Psycheceutical, Inc. has announced it has entered into a strategic agreement with Vici Health Sciences, known for providing pharmaceutical clients with tools to innovate and grow through new product development.…
Read More
03/01/2022 in Press Releases

Psycheceutical Announces Julian Bailes, M.D. as Principal Medical Advisor

Esteemed neurosurgeon to participate in strategy, direction for development of novel psychedelic therapy innovations.
Read More
01/20/2022 in Press Releases

Psycheceutical Completes Acquisition by Blue Water Ventures International

Psycheceutical, Inc., today announced the company has been fully acquired by Blue Water Ventures International, Inc. (OTCPK: BWVI).
Read More
11/18/2021 in Press Releases

Psycheceutical Grows Scientific Advisory Board With Addition of Translational Research Expert, Zachary Clayton, PhD

Psycheceutical, Inc., today announced the addition of Zachary Clayton, PhD, to its scientific advisory board.
Read More
09/28/2021 in Press Releases

Psycheceutical, Inc. Expands Executive Team With Announcement of New Advisory Board Appointments

Psycheceutical, Inc., today announced the growth of its esteemed board with two new appointments, Dr. Ronald Aung-Din and Dr. John Kutzko.
Read More
08/19/2021 in Press Releases

Psycheceutical, Inc. Announces New Patents That Enable Psychedelic Compounds to Be Administered as Pharmaceutical Medicines

Psycheceutical, Inc., today announced its exclusive license within the entire psychedelic industry of two major patents that will significantly advance the medical application of psychedelic compounds.
Read More

MEDIA CONTACT

Kaia Roman

VP, Strategy & Communications

kaia.roman@psycheceutical.com
Contact